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Objective:The association between carotid plaque calcification and clinical ischemic events is unclear. The aim of this study
was to systematically review published studies comparing degree of calcification between clinically symptomatic and
asymptomatic plaques.
Methods: A systematic search for relevant studies was performed in the PubMed/MEDLINE and Embase databases. For
studies reporting a rating scale or a continuous measure of calcification, study-specific and pooled standardized mean
differences (SMDs) between symptomatic and asymptomatic plaques were calculated. For studies reporting a dichoto-
mous measure, study-specific and pooled odds ratios (ORs) were calculated. If no significant heterogeneity was present
(I2 <50%), a fixed-effects pooling model was used. If significant heterogeneity was present (I2 >50%), a random-effects
pooling model was used, and sources of heterogeneity were explored by subgroup analyses.
Results: The 24 studies included in this systematic review used a wide range of methodologies to quantify degree of
calcification and a wide range of definitions to define clinically symptomatic and asymptomatic carotid plaques. Pooled
fixed-effects SMD of calcification volume or weight between symptomatic and asymptomatic plaques was 0.425 (95%
confidence interval [CI], 0.608 to 0.241); I2  39.3%. Pooled random-effects SMD of calcification percentage was
0.997 (95% CI, 1.793 to 0.200); I2  93.8. Subgroup analyses did not reveal homogeneous subgroups. Pooled
fixed-effects OR for the association between high degree of plaque calcification and symptoms was 0.696 (95% CI, 0.528
to 0.918); I2  21.1%.
Conclusion: The results of this systematic review suggest that clinically symptomatic plaques have a lower degree of
calcification than asymptomatic plaques. Assessment of degree of carotid plaque calcification may be useful to predict
which plaques will cause cerebrovascular ischemic events. ( J Vasc Surg 2010;51:1015-25.)Carotid artery atherosclerosis is an important cause of
stroke. Large randomized, controlled trials have demon-
strated a benefit of carotid endarterectomy (CEA) in pa-
tients with high-grade stenosis of the carotid artery lumen.1
However, many of these patients remain stroke-free even
with medical therapy alone.1 It is currently believed that
plaque features may be more predictive for stroke than
degree of luminal stenosis. Early identification of high-risk
lesions that can cause thromboembolic events, so-called
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doi:10.1016/j.jvs.2009.08.072vulnerable plaques, may tailor and improve treatment
strategies for individual patients, especially those with-
out symptoms. Histopathologic studies suggest that vul-
nerable plaques are characterized by a large lipid-rich ne-
crotic core (LRNC) with a thin overlying fibrous cap (FC),
extensive macrophage infiltration, and paucity of smooth
muscle cells.2,3 Although calcifications are present in ap-
proximately 50% to 60% of carotid plaques, their associa-
tion with cerebrovascular ischemic events is uncertain.4
Some investigators stated that calcified plaques may be
more biomechanically stable and less prone to disruption,5
whereas others stated that degree of plaque calcification
may predict stroke risk, independent of stenosis grade.6 In
addition, large prospective longitudinal ultrasonography
(US) scan studies found conflicting results on the asso-
ciation between plaque echogenicity and the occurrence
of stroke.7,8 These conflicting results might be explained
by differences in the methods for determining the degree
of plaque calcification. Moreover, characterization of
overall plaque echogenicity by standard B-mode US scan
may not adequately reflect degree of plaque calcifica-
tion.9,10
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to better determine the association between degree of
calcification in carotid plaques and clinical ischemic events.
METHODS
Data sources. A computer-aided search of the PubMed/
MEDLINE and Embase databases was conducted to find
relevant publications on the relation between carotid
plaque calcification and clinical cerebrovascular ischemic
symptoms. The search strategy is presented in Table I. No
beginning date limit was used. The search was updated
until May 4, 2009. To expand the search, the reference lists
of articles that finally remained after the selection process
were screened for other potentially suitable articles.
Study selection. Studies that compared degree of cal-
cification between clinically symptomatic and asymptom-
atic carotid plaques were eligible for inclusion. Only studies
that assessed degree of plaque calcification by ex vivo x-ray,
computed tomography (CT), magnetic resonance imaging
(MRI), magnetic resonance (MR) spectroscopy, histologic
or chemical analysis of CEA specimens,11 or by in vivo CT,
MRI, or B-mode US scan with pixel analysis (findings of all
these in vivo imaging modalities strongly correlate with
histologic measurements,12-14 were included. Studies as-
sessing overall plaque echogenicity by standard B-modeUS
scan were excluded, because it has been shown that char-
acterization of overall plaque echogenicity may not ade-
quately reflect degree of carotid plaque calcification.9,10 No
language restriction was applied. Review articles, meta-
analyses, abstracts, editorials or letters, case reports, and
studies performed on animals were excluded. Studies only
assessing degree of calcification of the intracranial carotid
artery were also excluded. Studies that provided a rating
scale or continuous measure were included only if they
provided sufficient data to calculate mean values and SDs of
the measurements, both for symptomatic and asymptom-
atic plaques. Studies that provided dichotomous measures
were included only if they provided sufficient data to con-
struct a 2 2 contingency table to calculate the odds ratio
(OR) of symptoms in relation to degree of carotid plaque
calcification. When data were presented in more than one
article, the article with the most details, or the most recent
Table I. Search strategy and results as of May 4, 2009
No. Search string
No. of articles
PubMed/MEDLINE Embase
1 Carotid 87,319 69,850
2 Atherosclerosis OR
arteriosclerosis OR
plaque OR atheroma
188,534 141,983
3 Calcif* OR calcium
OR bone OR
mineral
1,232,740 887,698
4 No. 1, 2, and 3 1118 1226
No., Number.article, was chosen. Using the aforementioned inclusionand exclusion criteria, titles and abstracts of the retrieved
articles were reviewed. Articles were rejected if they were
clearly ineligible. Of each article that was potentially eligible
for inclusion, the full-text version was retrieved. Full-text
versions were then reviewed to determine study eligibility
for inclusion.
Study analysis. For each included study, several study
characteristics were recorded (Table II). For studies using a
rating scale or continuous measure of degree of plaque
calcification, the measurements were standardized on a
uniform scale so that results of individual studies could be
combined. This was done by calculating the standardized
mean difference (SMD) for each study: first, mean values
and SDs of calcificationmeasurements for symptomatic and
asymptomatic plaques were extracted. For studies provid-
ing SEs, the SD was recalculated by the following formula:
SD SE * (sample size).15 Subsequently, the SMD was
calculated, which is the difference in mean calcification
measurements between symptomatic and asymptomatic
plaques, divided by an estimate of the within-group
SD.16,17 By expressing the outcome as SMD, the results
of individual studies could be combined since they have
no units.16,17 Studies measuring calcification volume or
weight were pooled, and studies measuring calcification
percentage were pooled. The pooled SMD across studies
was estimated by means of fixed and random-effects mod-
els.16 The fixed-effects pooling model is based on the math-
ematical assumption that a single common (or “fixed”) effect
underlies every study in the meta-analysis, whereas the
random-effects pooling model makes the assumption that
individual studies are estimating different effects.16 If the
95% confidence interval (CI) of the pooled SMD did not
overlap the referent (0.0), it was considered to be statisti-
cally significant. Thus, if the pooled SMD was significantly
greater than 0.0, symptomatic plaques had a higher
degree of calcification than asymptomatic plaques. If the
pooled SMD was significantly lower than 0.0, asymp-
tomatic plaques had a higher degree of calcification. For
studies using a dichotomous measure of degree of plaque
calcification, the number of symptomatic and asymptom-
atic plaques containing a high and low degree of calcifica-
tion were extracted. A standard correction of adding 0.5 to
all cells of the 2  2 contingency table was applied if there
were no plaques in one of the four cells. Study-specific ORs
were calculated, and the pooled OR across studies was
estimated by means of fixed and random-effects models.16
The OR is the odds of the event (high degree of calcifica-
tion) occurring in one group (symptomatic plaques) di-
vided by the odds of the event occurring in the other group
(asymptomatic plaques).16,18 If the 95% CI of the pooled
OR did not overlap the referent (1.0), it was considered to
be statistically significant. Thus, if the pooled OR was
significantly greater than one, symptomatic plaques were
more likely to have a high degree of calcification than
asymptomatic plaques. If the pooled OR was significantly
lower than one, asymptomatic plaques were more likely to
have a high degree of calcification. Results were graphically
displayed in forest plots (Figs 1-3).19 In these plots, bullets
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the bottom of the plots, bullets represent the pooled esti-
mate, both for the fixed and random-effects models. The
lines extending from the bullets represent the 95% CI for
the estimates. A vertical line through the referent (0.0 for
the SMD and 1.0 for the OR) was also plotted. If the
(pooled) 95% CI crosses this line, it indicates there is no
significant difference in degree of calcification between
symptomatic and asymptomatic plaques. Heterogeneity
was tested by calculating the I2 statistic.20 The test seeks
to determine whether there are genuine differences underly-
ing the results of the studies (heterogeneity) or whether the
variation in findings is compatible with chance alone (ho-
mogeneity). The I2 ranges from 0 (no heterogeneity) to
100% (all variance due to heterogeneity). Significant heter-
ogeneity was defined as I250%. If I2 was50%, emphasis
was placed on the fixed-effects pooling model. If I2 was
50%, emphasis was placed on the random-effects pooling
model, and potential sources for heterogeneity were ex-
plored by subgroup analysis. Covariates analyzed were:
country of origin (USA vs other countries), primary study
outcome (comparison of calcification in symptomatic and
asymptomatic carotid plaques as primary outcome vs com-
parison of calcification in symptomatic and asymptomatic
carotid plaques not as primary outcome), study design
(reported prospective study design vs no or unreported
prospective study design), way of patient recruitment (con-
secutive or random selection of patients vs nonconsecutive,
nonrandom selection, or unreported way of recruitment),
sample size (25 symptomatic and 25 asymptomatic
plaques vs25 symptomatic or25 asymptomatic plaques),
stenosis grade (no significant difference vs significant or unre-
ported difference between symptomatic and asymptomatic
plaques), method to analyze plaque calcification (ex vivo vs
in vivo analysis), way of interpretation (blinding vs no or
unreported blinding for symptomatic or asymptomatic sta-
tus). Potential presence of publication bias was assessed by
constructing funnel plots.16,21 Publication bias arises from
the tendency that studies with significant or “positive”
results have a better chance of being published than those
with nonsignificant or “negative” results. The subsequent
overrepresentation of studies with significant or positive
findings in a systematic review may mean that the review is
biased toward a positive or significant result. In a funnel
plot, the effect size (in this case the SMD or log OR) is
plotted vs a measure of its precision, such as sample size (in
this case represented by the SE). With increasing sample
size, random variations of the effect are smaller. Thus, data
from the included studies are expected to be symmetrically
distributed in an inverted funnel-shaped area of the plot if
there is a low likelihood of publication bias. Conversely,
an asymmetrical funnel plot may indicate a biased study
sample.16,21 However, it should be kept in mind that a
funnel plot is not a very reliable method of investigating
publication bias.16,22 Nevertheless, it does give some idea
of whether the study results are scattered symmetrically
around a central, more precise effect.16Statistical analyses were performed by using Statistical
Package for the Social Sciences software, version 11.5
(SPSS Inc, Chicago, Ill) and MedCalc software (MedCalc,
Mariakerke, Belgium).
RESULTS
Literature search. The computer-aided search re-
vealed 1118 articles from PubMed/MEDLINE and 1226
articles from Embase (Table I). Reviewing titles and ab-
stracts from PubMed/MEDLINE revealed 35 articles po-
tentially eligible for inclusion. Reviewing titles and ab-
stracts from Embase revealed 34 articles, of which 32 were
already identified by the PubMed/MEDLINE search.
Thus, 37 articles remained for possible exclusion and were
retrieved in full-text version. After reviewing the full article,
13 articles were excluded because they did not fulfill the
selection criteria,6,23-34 and one article35 could not be
retrieved and was not included in the analysis. Screening
references of the remaining articles revealed one article,
which was also included.36 Eventually, 24 studies9,14,36-57
were included in this systematic review (Table II).
Heterogeneity and pooled results. Wintermark et
al40 provided results for asymptomatic plaques from asymp-
tomatic patients (n  50) and for contralateral asymptom-
atic plaques from symptomatic patients (n  40). Only
results from the first group were used for meta-analysis and
assessment of heterogeneity. There was no significant het-
erogeneity across studies measuring calcification volume or
weight40-44,46,51,55 (I2  39.3%). Using a fixed-effects
model, pooled SMDbetween symptomatic and asymptom-
atic plaques was 0.425 (95% CI, 0.608 to 0.241).
The 95% CI of the pooled SMD did not cross the referent
0.0 (Fig 1), indicating that symptomatic plaques had lower
calcification volume or weight than asymptomatic plaques.
There was significant heterogeneity across studies measur-
ing calcification percentage14,42,45,47-50,53 (I2  93.8%).
Using a random-effects model, pooled SMD between
symptomatic and asymptomatic plaques was 0.997 (95%
CI, 1.793 to 0.200). The 95% CI of the pooled SMD
did not cross the referent 0.0 (Fig 2), indicating that
symptomatic plaques had a lower calcification percentage
than asymptomatic plaques. Exploration of sources of het-
erogeneity did not reveal homogeneous subgroups (for all
subgroups: I250.0%). There was no significant heteroge-
neity across studies using a dichotomous measure of degree
of plaque calcification9,36-39,52,54,56,57 (I2  32.4%).
Pooled OR, using a fixed-effects model, was 0.740 (95%
CI, 0.565-0.969). The 95% CI of the pooled OR did not
cross the referent 1.0 (Fig 3), indicating that plaques with a
low degree of calcification were more likely to be clinically
symptomatic. Visual assessment of the funnel plot on calci-
fication volume or weight (Fig 4,A) shows that it is roughly
symmetrical, which suggests a low likelihood of publication
bias. The funnel plot on calcification percentage (Fig 4, B)
is not symmetrical, although this impression is mainly
caused by one small study to the left of the most common
effect. This may indicate publication bias, but it may also be
due to study factors. The funnel plot on dichotomous
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Study year Country
Comparison of calcification in symptomatic
and asymptomatic carotid plaques as
primary study outcome Study design
Way of patient
recruitment
Romero, 2009 USA Yes Retrospective NR
Peeters, 2009 The Netherlands No Prospective Consecutive
Wahlgren, 2009 USA No NR NR
Wintermark, 2008 USA Yes Retrospective Consecutive
Raman, 2008 USA No Prospective NR
Nandalur, 2007 USA Yes Retrospective Consecutive
Uwatoko, 2007 Japan Yes NR Consecutive
Miralles, 2006 Spain Yes NR Consecutive
Baroncini, 2006 Brazil No NR Non consecutive
Saam, 2006 USA Yes Retrospective Consecutive
Lal, 2006 USA Yes Prospective NR
Serfaty, 2006 France Yes Prospective NR
Fisher, 2005 USA Yes NR NR
Nandalur, 2005 USA Yes Retrospective Consecutive
Shaalan, 2004 USA Yes Retrospective Consecutive
Gonçalves, 2003 Sweden Yes NR NR
Lal, 2002 USA Yes Prospective NR
Tegos, 2000 UK Yes NR NR
Kim, 2000 Korea Yes Retrospective NR
Montauban, 1999 The Netherlands No NR Consecutive
Carr, 1996 USA Yes Prospective NR
Seeger, 1995 USA Yes NR NR
Avril, 1991 France Yes Prospective Consecutive
Bassiouny, 1989 USA Yes NR NR
Study Definition of symptomatic carotid plaque
Romero, 2009 Ipsilateral anterior circulation stroke or TIA 1 month of CTA
Peeters, 2009 According to ECST and NASCET criteria
Wahlgren, 2009 TIA, AFx, or nondisabling stroke 6 months before CEA
Wintermark, 2008 Ipsilateral acute infarct and the likely cause of stroke was large-artery atherosclerosis. Exclusion: atrial fibrillation
Raman, 2008 Ipsilateral stroke or TIA and absence of other source of embolism
Nandalur, 2007 Ipsilateral stroke, TIA, or AFx 7 days of undergoing CT. Exclusion: conflicting sources of neurological symptoms
(cardiac emboli or lacunar infarcts)
Uwatoko, 2007 Ipsilateral symptomatic ischemic stroke, TIA, or AFx in the preceding 6 months
Miralles, 2006 Stroke, TIA, or AFx
Baroncini, 2006 Ipsilateral TIA, AFx, central retinal artery occlusion, CVA, silent infarcts, or lacunar symptomatology
Saam, 2006 Ipsilateral TIA, AFx, or stroke 4 months before MRI. Exclusion: other potential causes of symptoms, as assessed
by additional diagnostic tests, including brain CT, MRI, echocardiography, and holter monitoring
Lal, 2006 According to NASCET criteria
Serfaty, 2006 A carotid artery was considered symptomatic only if the patient had contralateral symptoms
Fisher, 2005 According to NASCET criteria
Nandalur, 2005 AFx, TIA, or stroke 1 week of CTA. Exclusion: concomitant conflicting laterizing ischemic symptoms, such as
those due to known cardiac thrombus or small vessel disease indicated by lacunar infarcts seen on CT and MRI
Shaalan, 2004 TIA, stroke, or AFx 6 months before CEA
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Symptomatic/asymptomatic plaques*
Method to assess stenosis grade
Symptomatic vs asymptomatic# plaques
37/38 CTA 82  5% vs 80  6% (P  .1093)
630/174 NR
9/21 NR
40/40 (all contralateral asymptomatic plaques in
symptomatic patients) and 50
CTA 29.1  4.9% vs 23.9  4.3% (contralateral asymptomatic plaques)
and 26.3  4.1% (P  .647 and .386)
11/28 DSA or contrast-enhanced MRA, NR
35/67 CTA 82.0  11.9% vs 79.4  10.8% (P  .05)
37/47 DSA and DUS, NR
13/13 CTA 60% vs 60% (P: NR)
15/10 DUS 70% vs 80% (P: NR)
23/23 (all contralateral asymptomatic plaques) MRI Mean lumen area: 26.6  14.0 mm2 vs 35.1  13.9 mm2 (P  .008)
18/27 (3 contralateral asymptomatic plaques) DUS, NR
30/102 (including contralateral asymptomatic plaques) CT 50% vs 50% (P: NR)
105/91 DSA Median: 64% (ipsilateral symptomatic plaques) and 67% (contralateral
symptomatic plaques) vs 75% (P: NR)
15/21 (including contralateral asymptomatic plaques) CT 60% vs 60% (P: NR)
25/23 DUS 76  16% vs 82  11% (P  .05)
14/16 (1 contralateral asymptomatic plaque) DUS 70% vs 80% (P: NR)
7/13 (1 contralateral asymptomatic plaque) DUS, NR
46/25 DUS Median: 90% vs 83% (P  .34)
38/17 DSA, NR
33/14 DSA and/or DUS 70% vs 70% (P: NR)
19/25 DSA or MRA 77  15% vs 74  17% (P  .57)
40/38 DSA and/or DUS 78.8  15.1% vs 78.0  12.1% (P: NR)
72/115 DUS and DSA NR (P  .084)
31/14 DSA 87  2% vs 89  2% (P  .05)
Definition of asymptomatic carotid plaque Method, calcification measure Blinding
No stroke or TIA, or stroke or TIA 1 month old,
not referable to the target artery
In vivo CT
Calcified vs noncalcified (calcified: density 130 HU and 50% of
the plaque volume)
NR
According to ACST criteria Histologic analysis
Moderate/heavy vs none/minor calcification
Yes
NR Histologic analysis
Calcified vs noncalcified
NR
No stroke or stroke in a distribution not consistent
with a carotid origin
In vivo CT
Calcification volume and percentage
Yes
NR Chemical analysis of CEA specimens
Calcium mg/g dry weight
NR
No history of symptoms, neither remote or at the
time of examination
In vivo CT
Calcification volume and percentage
Yes
Ipsilateral small-artery territory infarct or
hemodynamic failure on SPECT
In vivo CT
Calcification volume
Yes
NR In vivo CT
Calcification volume
NR
No history of recent neurologic symptoms or
nonspecific, nonhemispheric symptoms such as
dizziness and vertigo
Histologic analysis
Percentage calcification of the total plaque area
NR
NR In vivo MRI
Calcification volume
Yes
According to ACAS criteria B-mode US with pixel segmentation with tissue mapping
Percentage calcium of the total area of the plaque in longitudinal view
Yes
NR In vivo CT
Calcified vs noncalcified (calcified: % soft plaque tissue/calcification
40%)
Yes
According to ACAS criteria X-ray of CEA specimens
Percentage calcification of total plaque area
NR
No history of ischemic neurologic symptoms,
either remote or current
In vivo CT
Percentage calcification, median density 50 HU, 51-130 HU, or
130 HU
Yes
NR Ex vivo CT Yes
Percentage calcification of total plaque area
s in as
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suggesting a low likelihood of publication bias.
DISCUSSION
The results of this systematic review show that carotid
Fig 1. Forest plot of the association between plaque calcification
volume or weight and clinical ischemic symptoms; study-specific
and pooled standardized mean differences (SMDs) for studies
using a rating scale or continuous measure of calcification volume
or weight. Bullets represent each individual study’s SMD estimate.
At the bottom of the plot, bullets represent the pooled estimate,
both for the fixed and random-effects models. The lines extending
from the bullets represent the 95% confidence interval (CI) for the
estimates. A vertical line through the referent (0.0) has also been
plotted.
Table II. Continued.
Study Definit
Gonçalves, 2003 Ipsilateral AFx, TIA, or stroke 6 months. E
Lal, 2002 According to NASCET criteria
Tegos, 2000 Ipsilateral AFx, TIA, or stroke 3 months. E
cerebral hematoma
Kim, 2000 NR
Montauban, 1999 TIA, stroke, or AFx 1-6 weeks before CEA
Carr, 1996 Ipsilateral stroke, TIA, or AFx
Seeger, 1995 Ipsilateral TIA, AFx, or embolic CVA, and no
Avril, 1991 TIA, reversible ischemic neurologic deficits, m
Bassiouny, 1989 Ipsilateral TIA or reversible ischemic neurolo
ACAS, Asymptomatic carotid atherosclerosis study; ACST, Asymptomatic
computed tomography; CTA, computed tomography angiography; CVA
ultrasonography; ECST, European Carotid Surgery Trial;HU,Hounsfield u
NASCET, North American Symptomatic Carotid Endarterectomy Trial; N
transient ischemic attack; US, ultrasound scan.
*Unless otherwise indicated, data indicate number of asymptomatic plaque
#Unless otherwise indicated, data indicate mean degree of stenosis  SD.plaques which have lower calcification volume, weight, orpercentage, are more likely to be clinically symptomatic.
Results of studies measuring calcification volume or weight,
and studies using a dichotomous measure of degree of
plaque calcification, were homogeneous. Results of studies
Fig 2. Forest plot of the association between plaque calcification
percentage and clinical ischemic symptoms; study-specific and
pooled standardized mean differences (SMDs) for studies using a
rating scale or continuous measure of calcification percentage.
Bullets represent each individual study’s SMD estimate. At the
bottom of the plot, bullets represent the pooled estimate, both for
the fixed and random-effects models. The lines extending from the
bullets represent the 95% confidence interval (CI) for the esti-
mates. A vertical line through the referent (0.0) has also been
plotted.
symptomatic carotid plaque
ion: atrial fibrillation, aortic valve disease, mechanical heart valves
ion: cardioembolic conditions, lacunar symptomatology, or
r source of embolic material
stroke
ficit, AFx, stroke
d Surgery Trial; AFx, amaurosis fugax; CEA, carotid endarterectomy; CT,
rovascular accident; DSA, digital subtraction angiography; DUS, duplex
RA,magnetic resonance angiography;MRI,magnetic resonance imaging;
t reported; SPECT, single photon emission computed tomography; TIA,
ymptomatic patients.ion of
xclus
xclus
othe
inor
gic de
Caroti
, cereb
nits;M
R, nomeasuring calcification percentage were heterogeneous,
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subgroup analyses.
This systematic review has some potential limitations.
Due to the large methodologic differences among the
Fig 3. Forest plot of the association between degree of plaque
calcification and plaque clinical ischemic symptoms; study-specific
and pooled odds ratios (ORs) for studies using a dichotomous
measure of degree of plaque calcification. Bullets represent each
individual study’s standardized mean difference (SMD) estimate.
At the bottom of the plot, bullets represent the pooled estimate,
both for the fixed and random-effects models. The lines extending
from the bullets represent the 95% confidence interval (CI) for the
estimates. A vertical line through the referent (1.0) has also been
plotted.
Table II. Continued.
Definition of asymptomatic carotid plaque
NR Chemical an
Calcium hy
According to ACAS criteria B-mode US
Percentage
No history of symptoms on the side of interest Histologic a
Calcification
NR Histologic a
Calcium de
No cerebral ischemic symptoms Histologic a
Percentage
NR Histologic a
Predominan
Absence of ipsilateral TIA, AFx, or embolic CVA Chemical an
Calcium mg
NR Histologic a
Calcification
NR Histologic a
Calcificationstudies, the pooled results should be interpreted with cau-tion. There was large between-study variation in method-
ologies used to analyze plaque calcification.However, there
is no single gold standard reference and measurement
method for quantifying plaque calcification. The ex vivo
methods used by the included studies (histologic analysis,
CT, x-ray, and chemical analysis) are accepted methods
to quantify vascular calcification,11 and the in vivo meth-
ods (CT, MRI, and B-mode US scan with pixel analysis)
have shown to strongly correlate to histologic measure-
ments.12-14 Still, differences inmethodologies may account
for heterogeneity across studies. Furthermore, there were
considerable differences in the definition of symptomatic
and asymptomatic plaques across studies. Regarding symp-
tomatic status, only four studies14,38,47,48 stated that they
applied North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET)58 or European Carotid Surgery
Trial (ECST)59 selection criteria. According to these cri-
teria, patients with cardiac disease likely to cause embo-
lism were excluded, because in these cases, symptoms
may not be attributable to carotid atherosclerosis. Of the
remaining 20 studies, only 8 explicitly stated that they
excluded patients with a possible cardiac source of em-
bolism.9,40-42,46,49,51,55 Ten studies did not report whether
they excluded patients with a possible cardiac source of
embolism,37,39,43-45,50,52-54,56,57 whereas one study re-
ported to also include patients with atrial fibrillation.37 It is
debatable whether carotid plaques of patients with ipsilat-
eral lacunar infarcts should be defined as symptomatic. The
NASCET58 and ECST59 criteria do not specify this. Al-
though it is believed that lacunar infarcts are mainly caused
Method, calcification measure Blinding
s of CEA specimens
apatite mg/g wet weight
NR
pixel segmentation with tissue mapping
m of the total area of the plaque in longitudinal view
NR
is
o calcification at the level of the largest plaque area
Yes
is
vs no calcium deposit
NR
is
cation of total plaque volume
Yes
is
lcific vs predominantly noncalcific
Yes
s of CEA specimens
dry weight
NR
is
o calcification
NR
is
o calcification
Yesalysi
droxy
with
calciu
nalys
vs n
nalys
posit
nalys
calcifi
nalys
tly ca
alysi
/mg
nalys
vs n
nalys
vs nby small-vessel disease occluding a small perforating ar-
been added where the pooled estimate from the meta-analysis lies.
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from NASCET and ECST showed that CEA was also
beneficial in a subgroup of patients with a lacunar infarct on
CT.61 This indirectly suggests that there may also be a
causative relation between carotid stenosis (70%-99%) and
ipsilateral lacunar infarcts. In this systematic review, four of
the included studies9,40,42,49 reported to exclude patients
with lacunar infarcts, whereas one study did consider
plaques ipsilateral to lacunar infarcts as symptomatic.45 Of
the included studies, only Baroncini et al45 stated how
plaques of patients with silent infarcts were categorized. In
their study,45 these plaques were defined as symptomatic.
However, according to NASCET58 and ECST59 criteria,
patients must have experienced clinical symptoms to define
a plaque as symptomatic. On the other hand, it has recently
been shown that patients with asymptomatic carotid steno-
sis and an ipsilateral silent infarct onCT have a higher risk of
ipsilateral hemispheric neurologic events and stroke.62
Thus, the topic whether or not to define carotid plaques
ipsilateral to silent infarcts as symptomatic, is also contro-
versial. Remarkably, Serfaty et al36 classified carotid plaques
as symptomatic if there were contralateral symptoms. Fur-
thermore, vascular calcification is a dynamic process,63 and
degree of calcification of individual plaques may change over
time. There was a large variation in reported maximum time
interval between last symptoms and inclusion, which varied
from 1 week42,49 up to 6 months.14,38,39,43,47,48,50,51
Ten studies did not report the maximum time inter-
val.36,40,41,44,45,52,54-57
Regarding asymptomatic status, one study38 stated that
it applied Asymptomatic Carotid Surgery Trial (ACST)
selection criteria.8 According to these criteria,8 a carotid
plaque is considered to be asymptomatic if it had not
caused any stroke, transient cerebral ischemia, or other
relevant neurologic symptoms in the past 6 months.
Three studies14,47,48 used Asymptomatic Carotid Athero-
sclerosis Study (ACAS) methodology.64 However, in
ACAS,64 the definition of an asymptomatic carotid plaque
is vague. Eleven studies also did not specify how asymp-
tomatic plaques were defined.36,39,41,44,46,50-52,54,56,57
Seven studies defined carotid plaques as asymptomatic
when there was no history of ipsilateral ischemic symp-
toms.9,37,40,42,49,53,55 One study considered plaques of
patients without any history of recent neurologic symptoms
as asymptomatic but did not specify the time criterion they
applied.45 Another study defined plaques as asymptomatic
even when there was an ipsilateral small artery territory
infarct or ipsilateral ischemic event and hemodynamic fail-
ure on single photon emission CT.43 Aforementioned dif-
ferences in definition of symptomatic and asymptomatic
plaques may have been important sources of heterogeneity
and may have influenced the pooled results. However, due
to the large variation and relatively small number of studies,
these effects could not be explored by meaningful sub-
group analyses. Furthermore, when there is a difference in
degree of stenosis between symptomatic and asymptomatic
plaques, the presence or absence of symptoms may beFig 4. A, Funnel plots on studies using calcification volume or
weight, (B) calcification percentage, (C) and dichotomous calcifi-
cationmeasure. The vertical axis is a measure of the precision of the
effect size of a study, in this case represented by the SE of the
standardized mean difference (SMD) or log odds ratio (OR) (the
log OR was used, because it can take any value and has an
approximately normal distribution). The horizontal axis measures
the study’s effect size, in this case, the SMD or log OR. The point
estimate from each study has been plotted, and a vertical line hasattributed to this parameter rather than degree of plaque
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Volume 51, Number 4 Kwee 1023calcification. However, only eight studies reported that
there was no significant difference in degree of luminal
stenosis caused by symptomatic and asymptomatic
plaques.9,37,40,42,50,54,56,57 In addition, one study reported
that symptomatic plaques caused a higher degree of luminal
narrowing,46 which may explain why the SMD in that study
was higher than 0.0. Finally, 11 studies did not reportwhether
they assessed degree of plaque calcification blinded to clinical
information,14,37,39,41,44,45,48,51,52,55,56 which may have bi-
ased their results.
In the present systematic review, pooled SMD for
calcification volume or weight between symptomatic and
asymptomatic plaques was 0.425, whereas pooled SMD
for calcification percentage was 0.997, suggesting that
calcification percentage may be a stronger prognostic pa-
rameter for plaque stability. Plaques that have a higher
calcification percentage may have smaller LRNC size,
which could decrease plaque vulnerability. Abedin et al63
hypothesized that the relationship between calcification
and clinical events likely relates to mechanical instability
introduced by calcified plaque at its interface with softer,
noncalcified plaque and that larger interface area would
make plaques more prone to rupture. They also hypothe-
sized that as calcification proceeds, interface surface area
initially increases, but eventually decreases as plaques coa-
lesce.63 This could explain why plaques with a high degree
of calcification are less likely to produce clinical symptoms
compared with plaques that are moderately calcified. In
addition, it has also been reported that noncalcified carotid
plaques harbor a greater degree of FC inflammation, a key
process in FC disruption.39,50 Li et al65 suggested that the
location of calcification may be a critical factor in plaque
stability. Using a computational simulation, they showed
that the presence of calcification at the thin FC, close to the
lumen, may result in high stress concentrations, which
could increase the risk of plaque rupture. Calcification of
the FC at other locations further away from the lumen or
calcification deposits in the LRNC would have no or little
impact on plaque stress.65 This theory could not be con-
firmed by the present systematic review, because none of
the included studies assessed the frequency of calcification
located at the FC.
In conclusion, the studies included in this systematic
review used a wide range of methodologies to quantify
degree of calcification and a wide range of definitions to
define clinically symptomatic and asymptomatic carotid
plaques. Pooled results suggest that symptomatic carotid
plaques have a lower degree of calcification. Future studies
should use standardizedmethods and definitions and inves-
tigate whether in vivo assessment of degree of plaque
calcification is useful to predict which plaques will cause
future cerebrovascular ischemic events.
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